Alpine Immune Sciences – 10-K Report Revealed

By Bobby Samwell • Wednesday, March 20 10:36 • Permanent Link

Alpine Immune Sciences has recently released its annual report, providing an in-depth look at the company's financial performance and operations. The clinical-stage immunotherapy company, headquartered in Seattle, Washington, focuses on developing innovative protein-based immunotherapies for autoimmune and inflammatory diseases. Alpine Immune Sciences has strategic collaborations with biopharmaceutical companies and a pipeline of clinical and preclinical candidates in development, including Povetacicept and Acazicolcept.

In the "Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations" section, Alpine Immune Sciences outlined its strategic focus on discovering and developing modern therapies to treat patients with serious autoimmune and inflammatory diseases. The company's lead wholly-owned program, Povetacicept, is being advanced in clinical studies for the treatment of multiple B cell and/or autoantibody-related diseases. Alpine Immune Sciences is also working to complete its obligations under the amended AbbVie Agreement for Acazicolcept, including the delivery of an agreed-upon data package to AbbVie.

Financially, Alpine Immune Sciences reported collaboration revenue primarily from its collaboration and licensing agreements with AbbVie, Amgen, and Adaptimmune. The company expects revenue to fluctuate from quarter to quarter and is actively seeking additional capital to fund its operations, including nonclinical studies and clinical trials for its product candidates, manufacturing, research and development efforts, and expansion of its intellectual property portfolio.

As of December 31, 2023, Alpine Immune Sciences had cash, cash equivalents, restricted cash, and investments totaling $368.2 million. The company reported a net loss of $32.2 million for the year ended December 31, 2023, and $57.8 million for the year ended December 31, 2022. Alpine Immune Sciences anticipates incurring significant expenses and operating losses for at least the next several years as it continues to advance its product candidates and pursue its research and development efforts.

Today the company's shares have moved 3.7% to a price of $41.42. For the full picture, make sure to review Alpine Immune Sciences's 10-K report.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.